Abbvie Inc (ABBV)

$189.28 -1.47 (-0.77%)
Market Cap 336.94B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 18.50
Forward PE 15.47
Profit Margin 7.59%
Debt to Equity Ratio 47.80
Volume 3,706,200
Avg Vol 6,863,058
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 70%
Beta 0.48
Analysts Strong Sell
Price Target $208.88

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 3 at 9:38 PM
AbbVie ($ABBV) is strategically positioned in the booming GPRC5D-directed therapies market, with its candidate SIM0500 advancing in the pipeline. As the multiple myeloma treatment landscape evolves, AbbVie's focus on novel immunotherapies could unlock significant growth—though their high debt load remains a watchpoint. Bullish on their R&D execution. https://www.prnewswire.com/news-releases/gprc5d-directed-therapies-market-is-anticipated-to-gain-momentum-during-the-forecast-period-20252034-owing-to-unmet-need-in-multiple-myeloma--delveinsight-302497458.html
0 · Reply
smartkarma
smartkarma Jul. 3 at 5:22 PM
📈 Earnings Alert $ABBV - AbbVie Sees 2Q IPR&D and Milestones Expense of $823M: ∙ Sees Adj EPS $2.84 to $2.88 https://www.smartkarma.com/entities/abbvie-inc
1 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 3 at 5:11 PM
$ABBV takes a $823M hit from R&D acquisitions, trimming 2025 EPS guidance to $11.67-$11.87. Short-term pain for long-term pipeline growth? Bulls see strategic positioning, bears eye that $64.7B debt mountain. Today's dip could test investor patience with the 3.5% yield. https://www.sec.gov/Archives/edgar/data/1551152/000155115225000034/abbv-20250703.htm
0 · Reply
BRNDN
BRNDN Jul. 3 at 3:29 PM
$ABBV looks like a good buying opp
1 · Reply
Quantumup
Quantumup Jul. 3 at 3:04 PM
Morgan Stanley assumed $ARQT Overweight-$20 and said, "Focus remains on Zoryve commercial execution and its share gains within the branded, non-steroidal topical dermatology products." $AMGN $ABBV $JNJ LLY NVS $NKTR Morgan Stanley added, "We estimate peak sales for Zoryve cream in PsO and AD of $266M and $189M, respectively, and peak for Zoryve foam in seb. derm and scalp PsO of $267M and $77M. Morgan Stanley went on to say:
0 · Reply
OptionSamurai
OptionSamurai Jul. 3 at 2:53 PM
$ABBV appears in our scan that looks for calls that will explode if the stock goes to analyst target. ✔ Analysts rating is BUY ✔ The analyst target price is 12.9% away ✔ IV Percentile is 68.7% Call 195.0, 19-Sep-25 has: 💀 Max loss of 3.3% compared to holding shares ⚖ Breakeven is 6.1% away 📈 If the stock hits the target, the call will profit 203% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
CreamCramer
CreamCramer Jul. 3 at 1:33 PM
$CYBN still holding? ask yourself, why didnt i listen to the people who told you this would happen? why did you believe pumpers? what the people who were right saying now? it may save you money next time: save your ego, it doesnt pay bills, sell this junk if it jumps to 8$ if not exit and invest in something real like $ABBV $200 lost in 24hrs for every 100 shares owned of Dilution Doug's $CYBN today pernix before, where will he go next? Doug thanks you for your service 🫡
1 · Reply
MontanaT
MontanaT Jul. 3 at 2:04 AM
$ABBV $4.21 and still long way to still go… $10+ easy money don’t miss the train…
0 · Reply
theDIOyears
theDIOyears Jul. 3 at 12:09 AM
$BIIB Are we finally in an uptrend? I hope. Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration. The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA. It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025. Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's. They have earnings on July 31st, 2025. I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks. God speed $VRTX $OGN $ABBV $BCRX
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 5:05 PM
$ABBV ramps up deal-making — what's the strategy? 🧠💼 AbbVie is strengthening its pipeline with over 20 early-stage deals, including a $2.1B acquisition of Capstan Therapeutics, adding potential first-in-class CAR-T therapy and CellSeeker platform technology for RNA delivery. The Zacks Consensus Estimate for 2025 EPS has edged higher from $12.26 to $12.28, reflecting strategic growth moves. See what makes this investment case strong 👉 https://www.zacks.com/commentary/2560194/will-abbvies-acquisition-spree-aid-pipeline-growth?cid=sm-stocktwits-2-2560194-body-589&ADID=SYND_STOCKTWITS_TWEET_2_2560194_BODY_589
0 · Reply
Latest News on ABBV
AbbVie Stock At $190: Premium Pricing For A Transformation Story

Jul 2, 2025, 10:50 AM EDT - 1 day ago

AbbVie Stock At $190: Premium Pricing For A Transformation Story

AbbVie to buy Capstan Therapeutics for up to $2.1 billion

Jun 30, 2025, 8:42 AM EDT - 3 days ago

AbbVie to buy Capstan Therapeutics for up to $2.1 billion

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

Jun 30, 2025, 8:31 AM EDT - 3 days ago

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 30, 2025, 8:25 AM EDT - 3 days ago

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

Jun 30, 2025, 8:00 AM EDT - 3 days ago

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

This Changes Everything: One Of The Most Important Shifts For Dividend Investors

Jun 30, 2025, 7:30 AM EDT - 3 days ago

This Changes Everything: One Of The Most Important Shifts For Dividend Investors

AM ARKK CAT CNQ EEM EGP ELS

Best Dividend Aristocrats For July 2025

Jun 29, 2025, 7:19 AM EDT - 4 days ago

Best Dividend Aristocrats For July 2025

ABT ADM ADP AFL ALB AMCR AOS

Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer

Jun 25, 2025, 8:58 AM EDT - 8 days ago

Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer

My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys

Jun 25, 2025, 8:10 AM EDT - 8 days ago

My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys

AAPL AGNC AM APLE ARCC ARI AVGO

2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'

Jun 24, 2025, 8:00 AM EDT - 9 days ago

2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'

BKH

3 dividend stocks investors can look for stability as Iran attacks US base in Qatar

Jun 23, 2025, 3:05 PM EDT - 10 days ago

3 dividend stocks investors can look for stability as Iran attacks US base in Qatar

KO PG

I'm Buying Dividend Giants At Huge Discounts

Jun 20, 2025, 9:00 AM EDT - 13 days ago

I'm Buying Dividend Giants At Huge Discounts

BMY CVX OXY PFE SHEL SLB TTE

AbbVie Declares Quarterly Dividend

Jun 20, 2025, 8:00 AM EDT - 13 days ago

AbbVie Declares Quarterly Dividend

AbbVie's migraine drug meets main goal of late-stage study

Jun 18, 2025, 7:27 AM EDT - 15 days ago

AbbVie's migraine drug meets main goal of late-stage study

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

Jun 18, 2025, 7:15 AM EDT - 15 days ago

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Jun 17, 2025, 10:00 AM EDT - 16 days ago

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

AMGN JNJ MRK PFE

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow

Jun 17, 2025, 6:42 AM EDT - 16 days ago

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow

AbbVie says blood cancer drug fails late-stage trial

Jun 16, 2025, 9:12 AM EDT - 17 days ago

AbbVie says blood cancer drug fails late-stage trial

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

Jun 16, 2025, 9:00 AM EDT - 17 days ago

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

AbbVie: Margin Clarity, Dividend Durability Awaited

Jun 16, 2025, 5:05 AM EDT - 17 days ago

AbbVie: Margin Clarity, Dividend Durability Awaited

AbbVie Moves From Blockbuster Loss To Market Domination

Jun 16, 2025, 1:29 AM EDT - 17 days ago

AbbVie Moves From Blockbuster Loss To Market Domination

AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth

Jun 15, 2025, 8:30 AM EDT - 18 days ago

AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth

AbbVie's Post-Humira Strategy Is Paying Off For Investors

Jun 15, 2025, 7:11 AM EDT - 18 days ago

AbbVie's Post-Humira Strategy Is Paying Off For Investors

Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie

Jun 13, 2025, 1:57 PM EDT - 20 days ago

Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie

APD NFLX NRG

Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight

Jun 12, 2025, 1:00 PM EDT - 21 days ago

Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

Jun 11, 2025, 12:31 PM EDT - 22 days ago

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 11, 2025, 1:36 AM EDT - 22 days ago

AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

Jun 6, 2025, 4:08 PM EDT - 27 days ago

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

ABT JNJ LLY UNH XLV

June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs

Jun 4, 2025, 8:13 AM EDT - 4 weeks ago

June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs

ABM ADM ADP BDX BKH CWT FRT

Bert's May 2025 Dividend Income Summary

Jun 3, 2025, 1:43 PM EDT - 4 weeks ago

Bert's May 2025 Dividend Income Summary

C CZNC KMI NSC O PG SBUX

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

Jun 3, 2025, 8:15 AM EDT - 4 weeks ago

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 4 weeks ago

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Put Cash To Work: 2 Magnificent Dividends I'm Betting On

Jun 2, 2025, 10:00 AM EDT - 4 weeks ago

Put Cash To Work: 2 Magnificent Dividends I'm Betting On

RTX

Final Trades: JPMorgan, Meta, Abbvie and Gap

May 30, 2025, 4:20 PM EDT - 4 weeks ago

Final Trades: JPMorgan, Meta, Abbvie and Gap

META GAP JPM

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

May 30, 2025, 8:00 AM EDT - 4 weeks ago

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does

May 29, 2025, 7:30 AM EDT - 5 weeks ago

When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does

LMT VICI

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies

May 28, 2025, 8:00 AM EDT - 5 weeks ago

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies

Best Dividend Aristocrats For June 2025

May 27, 2025, 10:15 PM EDT - 5 weeks ago

Best Dividend Aristocrats For June 2025

ABT ADM ADP AFL ALB AMCR AOS

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

May 27, 2025, 9:00 AM EDT - 5 weeks ago

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs

May 20, 2025, 3:55 PM EDT - 6 weeks ago

69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs

ADM ALB AMCR APD ATO BEN CVX

3 Stocks That Will Profit From Trump's Drug Price Cut

May 16, 2025, 1:08 PM EDT - 6 weeks ago

3 Stocks That Will Profit From Trump's Drug Price Cut

LLY NVO

Is It Time To Buy AbbVie Stock At $180?

May 16, 2025, 8:30 AM EDT - 6 weeks ago

Is It Time To Buy AbbVie Stock At $180?

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV

May 15, 2025, 5:45 AM EDT - 7 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV

Jim Cramer talks good companies getting pummeled by rising interest rates

May 14, 2025, 8:00 PM EDT - 7 weeks ago

Jim Cramer talks good companies getting pummeled by rising interest rates

BMY CL GM JNJ PEP PG

Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer

May 14, 2025, 4:36 PM EDT - 7 weeks ago

Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer

PFE

AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 3:10 PM EDT - 7 weeks ago

AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)

Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's

May 14, 2025, 1:35 PM EDT - 7 weeks ago

Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's

HOOD LOW UNH

US FDA approves AbbVie's drug for a type of lung cancer

May 14, 2025, 1:23 PM EDT - 7 weeks ago

US FDA approves AbbVie's drug for a type of lung cancer

Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 3 at 9:38 PM
AbbVie ($ABBV) is strategically positioned in the booming GPRC5D-directed therapies market, with its candidate SIM0500 advancing in the pipeline. As the multiple myeloma treatment landscape evolves, AbbVie's focus on novel immunotherapies could unlock significant growth—though their high debt load remains a watchpoint. Bullish on their R&D execution. https://www.prnewswire.com/news-releases/gprc5d-directed-therapies-market-is-anticipated-to-gain-momentum-during-the-forecast-period-20252034-owing-to-unmet-need-in-multiple-myeloma--delveinsight-302497458.html
0 · Reply
smartkarma
smartkarma Jul. 3 at 5:22 PM
📈 Earnings Alert $ABBV - AbbVie Sees 2Q IPR&D and Milestones Expense of $823M: ∙ Sees Adj EPS $2.84 to $2.88 https://www.smartkarma.com/entities/abbvie-inc
1 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 3 at 5:11 PM
$ABBV takes a $823M hit from R&D acquisitions, trimming 2025 EPS guidance to $11.67-$11.87. Short-term pain for long-term pipeline growth? Bulls see strategic positioning, bears eye that $64.7B debt mountain. Today's dip could test investor patience with the 3.5% yield. https://www.sec.gov/Archives/edgar/data/1551152/000155115225000034/abbv-20250703.htm
0 · Reply
BRNDN
BRNDN Jul. 3 at 3:29 PM
$ABBV looks like a good buying opp
1 · Reply
Quantumup
Quantumup Jul. 3 at 3:04 PM
Morgan Stanley assumed $ARQT Overweight-$20 and said, "Focus remains on Zoryve commercial execution and its share gains within the branded, non-steroidal topical dermatology products." $AMGN $ABBV $JNJ LLY NVS $NKTR Morgan Stanley added, "We estimate peak sales for Zoryve cream in PsO and AD of $266M and $189M, respectively, and peak for Zoryve foam in seb. derm and scalp PsO of $267M and $77M. Morgan Stanley went on to say:
0 · Reply
OptionSamurai
OptionSamurai Jul. 3 at 2:53 PM
$ABBV appears in our scan that looks for calls that will explode if the stock goes to analyst target. ✔ Analysts rating is BUY ✔ The analyst target price is 12.9% away ✔ IV Percentile is 68.7% Call 195.0, 19-Sep-25 has: 💀 Max loss of 3.3% compared to holding shares ⚖ Breakeven is 6.1% away 📈 If the stock hits the target, the call will profit 203% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
CreamCramer
CreamCramer Jul. 3 at 1:33 PM
$CYBN still holding? ask yourself, why didnt i listen to the people who told you this would happen? why did you believe pumpers? what the people who were right saying now? it may save you money next time: save your ego, it doesnt pay bills, sell this junk if it jumps to 8$ if not exit and invest in something real like $ABBV $200 lost in 24hrs for every 100 shares owned of Dilution Doug's $CYBN today pernix before, where will he go next? Doug thanks you for your service 🫡
1 · Reply
MontanaT
MontanaT Jul. 3 at 2:04 AM
$ABBV $4.21 and still long way to still go… $10+ easy money don’t miss the train…
0 · Reply
theDIOyears
theDIOyears Jul. 3 at 12:09 AM
$BIIB Are we finally in an uptrend? I hope. Biogen (BIIB)'s LEQEMBI, Is currently approved for intravenous infusion administration. The maintenance dose subcutaneous use version that can be administered at home has a tentative regulatory decision date issued by the FDA. It is called the Prescription Drug User Fee Act (PDUFA) , it is on August 31, 2025. Also remember that screening for Alzheimer's disease just got a lot easier because in May 16th 2025 the FDA approve the first and only blood screening test for Alzheimer's. They have earnings on July 31st, 2025. I'm expecting the price to bounce between the upper and lower BOLL bands in the next few weeks. God speed $VRTX $OGN $ABBV $BCRX
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 5:05 PM
$ABBV ramps up deal-making — what's the strategy? 🧠💼 AbbVie is strengthening its pipeline with over 20 early-stage deals, including a $2.1B acquisition of Capstan Therapeutics, adding potential first-in-class CAR-T therapy and CellSeeker platform technology for RNA delivery. The Zacks Consensus Estimate for 2025 EPS has edged higher from $12.26 to $12.28, reflecting strategic growth moves. See what makes this investment case strong 👉 https://www.zacks.com/commentary/2560194/will-abbvies-acquisition-spree-aid-pipeline-growth?cid=sm-stocktwits-2-2560194-body-589&ADID=SYND_STOCKTWITS_TWEET_2_2560194_BODY_589
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 2 at 4:22 PM
$SLS $ABBV $PG $ALT $JNJ Has anybody else built a risk-weighted hybrid equity/options strategy calculator? Mine's working pretty well, but I'm curious to see if anybody would share theirs (I'd share mine in turn) so I can see how they put in their r-tolerance, delta weighting and IV decay models. I'm noticing the last couple of years, this seems to be my hiccup ( even though it's worked out heavily in my favor) in this clown market. TIA
0 · Reply
NvidiaKing
NvidiaKing Jul. 2 at 1:49 PM
$ABBV pos company
0 · Reply
ZacksResearch
ZacksResearch Jul. 2 at 11:48 AM
$ABBV is betting big on pipeline power 💥 With a $2.1B Capstan buy and 20+ deals lately, ABBV is stacking assets in immunology and more to fuel long-term growth. See what this acquisition spree means for the stock 👉 https://www.zacks.com/stock/news/2560194/will-abbvies-acquisition-spree-aid-pipeline-growth?cid=sm-stocktwits-2-2560194-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2560194_TEASER
0 · Reply
StagflationRecession
StagflationRecession Jul. 2 at 1:32 AM
$ABBV Up +$6 on a $2B acquisition... Really ?? lol
2 · Reply
JaredSotken
JaredSotken Jul. 1 at 11:24 PM
$ABBV ⚠️
0 · Reply
Quantumup
Quantumup Jul. 1 at 7:19 PM
Citizens reiterated $ONC Market Outperform-$348: "During the 2025 R&D day, the company highlighted key clinical data for Sonrotoclax + Zanubrutinib in TN and R/R CLL/SLL, as well as the BTK degrader BGB-16673 in R/R WM and R/R CLL/SL, which we view as best-in-class molecules with the potential to take the company to the next valuation inflection point. In addition to spelling out the "secret sauce" that allows the company to be one of the industry's leaders in successfully developing best-in-class oncology drugs, new data from several POC studies were presented. With Brukinsa on track to generate ~$3.7B+ for the company in 2025, one of the largest pipelines across all stages of clinical and preclinical development, and a strong cash position of $2.5B, we continue to believe BeOne shares are undervalued and represent a compelling investment opportunity, especially given the recent sell-off in shares." $ZLAB $ABBV AMGN NRIX AZN $LLY $PFE KYMR NUVL RVMD ARGX ASND ALNY
0 · Reply
Pacificstock27
Pacificstock27 Jul. 1 at 4:18 PM
$ABBV up $5-$6 today whats going on
0 · Reply
Garibs
Garibs Jul. 1 at 3:48 PM
$ABBV sept calls print 💵
0 · Reply
ZacksResearch
ZacksResearch Jul. 1 at 3:32 PM
$ABBV just dropped $2.1B on Capstan — here’s why it matters 👀 The buyout adds a novel in-vivo CAR-T therapy and tLNP platform to strengthen AbbVie's immunology pipeline. Full breakdown of the deal here 👉 https://www.zacks.com/stock/news/2559650/abbv-to-boost-immunology-pipeline-with-capstan-buyout-for-21b?cid=sm-stocktwits-2-2559650-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2559650_TEASER
0 · Reply
PanicSeller8
PanicSeller8 Jul. 1 at 3:19 PM
$ABBV Day like today is a reminder why you own it.
1 · Reply
ZacksResearch
ZacksResearch Jul. 1 at 1:14 PM
$ABBV on an acquisition spree! 🚀 The latest move? A $2.1 billion buyout of Capstan Therapeutics, adding a potential first-in-class CAR-T therapy to its immunology pipeline. This is part of AbbVie's strategic push, with over 20 early-stage deals since the beginning of 2024, pending customary closing conditions including regulatory approvals. Discover the full impact for AbbVie here 👉 https://www.zacks.com/commentary/2559650/abbv-to-boost-immunology-pipeline-with-capstan-buyout-for-21b?cid=sm-stocktwits-2-2559650-body-517&ADID=SYND_STOCKTWITS_TWEET_2_2559650_BODY_517
0 · Reply
BinaryLogic
BinaryLogic Jul. 1 at 9:51 AM
$VTYX Bull flag on the 1YR Daily and support lines at $1.85 and $2.04 respectively. Multiplier upside on this Company (IMO) on possible acquisition and/or successful product development. I have already provided possible buyout candidates ($LLY $ABBV), and if you cross-reference their product pipelines, you will likely agree.
0 · Reply